Date post: | 07-Jul-2015 |
Category: |
Health & Medicine |
Upload: | cadth-acmts |
View: | 521 times |
Download: | 0 times |
CADTH Patient EngagementActivities
DR. BRIAN O’ROURKE
CADTH PRESIDENT AND CEO
Best Medicines Coalition Annual Conference
Toronto, Ontario
November 17, 2014
Who and what is CADTH?
• Private, not-for-profit corporation
• Major producer of HTA for drugs, devices, diagnostics, and procedures
• Recognized globally as a leader in HTA
• 160 employees
• Funded by Health Canada, Provinces and Territories
CADTH Products and Services
• Drug formulary reviews
• Drug therapeutic class reviews
• Rapid response reviews
• Environmental and horizon scans
• HTA and optimal use reports
• HTA coordination and brokering services
• HTA methods guidance documents
• Education and training on HTA
CADTH Common Drug Review and pan-Canadian Oncology Drug Review
� National processes for:
• conducting objective, rigorous, and timely clinical and economic reviews of drugs, and
• providing formulary listing recommendations to participating publicly funded drug plans
Common Drug Review Update
• CDR backlog down to 7 submissions
o On track to eliminate backlog by March 2015
• Industry application fees implemented September 2014
• Study conducted recently to assess the impact of patient input to CDR
Pan-Canadian Oncology Drug Review: Phase II of Transfer
• pCODR and CDR will remain as independent programs
• Alignment of CDR and pCODR evaluation criteria
• Building on efficiencies and best practices from both programs
• Steering committee established with representation from drug plans and cancer agencies
Patient Engagement
Patients Help Define Value
Real shared decision-making ‘involves finding out
what matters to the patient – what is at stake for
them – and making judicious use of professional
knowledge and status and introducing research
evidence in a way that informs a dialogue about
what best to do, how and why.’
From Greenhalgh & Evidence Based Medicine Renaissance Group, BMJ, June 2014.
Patient Engagement at CADTH
• Common Drug Review
• pan-Canadian Oncology Drug Review
• Therapeutic Reviews
• Scientific Advice Program
• Patient Liaison Forum
What Does the Future Hold?
Patient HTA Navigator Role
• pCODR working with Canadian Cancer Action Network on a pilot project: Patient HTA Navigator
• Providing patient groups with support to optimize patient submissions for drugs under review by pCODR
o builds on the publication of A Guide for Patient Advocacy Groups: How to provide patient and caregiver input for a pCODR drug review.
Patient HTA Navigator Webinar
Webinar on November 21 from 1:00 p.m. to 2:00 p.m. – register
at www.ccanceraction.ca
CADTH’s Scientific Advice Program
• Program will offer advice to pharmaceutical companies on early drug development
• Companies will report on patient engagement activities related to clinical trial design
• CADTH will interview patient representatives to inform advice to companies
Patient Input to Medical Devices HTA
CADTH Strategic Plan 2015-2018
Includes a strategic objective on patient engagement:
“Embrace evolving successes in patient
engagement practices in health technology
assessment.”
CADTH 2015 Symposium: Student and Patient Group Award Programs
• New: Funding available for patient groups
• Not-for-profit, patient-related organizations, or citizen’s organizations interested in health policy
• Funding decisions based on financial need and contributions to conference
• Maximum award for both programs: $1,500.00
• Applications to [email protected] by December 5, 2014
Some thoughts to consider
• Patient input to scientific advice
• Patient input to medical devices HTA
• On-going engagement to CADTH initiatives and programs (CDR and pCODR)
• A new funding model for patient groups
• Impact of patient input to HTA and funding decisions
• What are some of the evolving successes in patient engagement that CADTH should embrace?